SCHEMBL20239309

SCHEMBL20239309

COc1ccc(CNc2cc(C#N)cc(Oc3ccc(CS(N)(=O)=O)cc3)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.46
CLK4 Q9HAZ1 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 1/20 0.44
HTT P42858 1/20 0.44
TSHR P16473 2/20 0.43
VNN1 O95497 2/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
PTGS2 P35354 1/20 0.41
PDE5A O76074 1/20 0.41
HRH4 Q9H3N8 1/20 0.41
GAA P10253 3/20 0.41
MAPT P10636 3/20 0.41
ALDH1A1 P00352 3/20 0.40
MAPK1 P28482 2/20 0.40
DGAT2 Q96PD7 1/20 0.40
CNR1 P21554 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20239145 0.90 DYRK1A (0.46) DYRK1ACLK4SMN1; SMN2LMNAHTT
SCHEMBL20472863 0.86 DYRK1A (0.46) DYRK1ACLK4SMN1; SMN2LMNAHTT
SCHEMBL20239228 0.85 LOXL2 (0.47) DYRK1ACLK4TSHRCA12CA1
SCHEMBL24690170 0.85 HTT (0.57) DYRK1ACLK4SMN1; SMN2LMNAHTT
SCHEMBL30019455 0.85 HTT (0.57) DYRK1ACLK4SMN1; SMN2LMNAHTT
SCHEMBL20239218 0.80 DGAT2 (0.47) CLK4VNN1CA12CA1CA2
SCHEMBL20239250 0.80 DGAT2 (0.57) DYRK1ACLK4LMNAVNN1CA12
SCHEMBL20239236 0.79 POLB (0.49) DYRK1ACLK4SMN1; SMN2LMNAHTT
SCHEMBL20239277 0.78 GRM5 (0.45) SMN1; SMN2LMNAHTTCA12CA1
SCHEMBL20239179 0.78 ACACB (0.48) DYRK1ACLK4SMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DYRK1A 3210/4885CLK4 2907/4885SMN1; SMN2 4828/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT DYRK1A 3037/4885CLK4 3193/4885SMN1; SMN2 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.